Study details
Enrolling now
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
University of California, San Diego
NCT IDNCT04883255ClinicalTrials.gov data as of Apr 2026
Phase
EARLY_PHASE1
Target enrollment
138
Study length
about 2.8 years
Ages
18–65
Locations
1 site in CA
What this study is about
Researchers are testing how different cannabis treatments affect cognitive functions like decision-making and attention in people with HIV. The trial will also measure levels of endocannabinoids (chemicals that interact with the body's natural cannabinoid system) to see if cannabis use impacts these systems.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take 10 mg Δ9-tetrahydrocannabinol (THC)
- 2.Take 600 mg cannabidiol (CBD)
- 3.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
dronabinol, cannabidiol, cannabinoid
Drug routes
oral (Oral Solution)
Body systems
Immune, Infectious